Kala Pharmaceuticals, Inc. (KALA)
Market Cap | 26.30M |
Revenue (ttm) | 420,000 |
Net Income (ttm) | -8.64M |
Shares Out | 2.54M |
EPS (ttm) | -0.12 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,863 |
Open | 10.59 |
Previous Close | 10.69 |
Day's Range | 10.29 - 10.82 |
52-Week Range | 3.54 - 56.72 |
Beta | -1.50 |
Analysts | Strong Buy |
Price Target | 24.00 (+132.01%) |
Earnings Date | Nov 7, 2023 |
About KALA
KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical d... [Read more]
Full Company ProfileFinancial Performance
In 2022, KALA's revenue was $3.89 million, a decrease of -65.37% compared to the previous year's $11.24 million. Losses were -$44.82 million, -68.57% less than in 2021.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for KALA stock is "Strong Buy" and the 12-month stock price forecast is $24.0.
News

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ARLINGTON, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside...

KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
ARLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative...

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-- Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED; topline data targeted for 2Q 2024 -- -- Combangio, Inc., a wholly owned subsidiary of KALA, awarde...

KALA BIO to Participate in Upcoming Investor Conferences in August
ARLINGTON, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative ...

Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ARLINGTON, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement aw...

Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference
ARLINGTON, Mass., June 02, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-- Announced positive data from initial safety portion of CHASE Phase 2b clinical trial of KPI-012; now enrolling primary safety and efficacy portion of trial, with topline data targeted in 1Q 2024 --...

Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED
MENLO PARK, Calif. and ARLINGTON, Mass., April 28, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development ...

Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED
--No safety issues identified in Cohort 1 -- -- Now proceeding to Cohort 2 to evaluate the safety and efficacy of two doses of KPI-012 in a multicenter, randomized, double-masked, vehicle-controlled t...

Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
ARLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization o...

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
-- Enrolled first patient in CHASE Phase 2b clinical trial evaluating KPI-012 for PCED; Top-line data targeted for 1Q 2024 -- -- Closed $31.0 million private placement financing, extending cash runway...

Kala Pharmaceuticals Up 400% In The Past Month, What's Next?
Kala pharmaceuticals underwent a massive rally over the past few days, and by all indications, the stock price is now headed toward a bottom.

Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment
Shares of Kala Pharmaceuticals Inc. KALA, +39.53% have rocketed higher in for three-straight sessions, toward a more-than 8-fold gain, since the biopharmaceutical company announced positive news regar...

Kala Pharmaceuticals Stock Continues To Soar: What's Going On? - Kala Pharmaceuticals (NASDAQ:KALA)
Kala Pharmaceuticals Inc KALA shares are trading higher Thursday. The stock appears to be moving on continued momentum after the company on Wednesday announced FDA acceptance of an investigational new...

Kala Pharmaceuticals stock rockets after FDA accepts IND application for PCED treatment
Shares of Kala Pharmaceuticals Inc. KALA, +1.03% shot up 45.7% in premarket trading Wednesday, after the biopharmaceutical company said the Food and Drug Administration accepted its investigational ne...

Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED
-- On-track to initiate Phase 2b trial in 1Q 2023; Topline data expected in 1Q 2024 -- -- Received remaining $25 million investment under previously announced private placement financing -- ARLINGTON...

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect
-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 -- -- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing,...

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing
ARLINGTON, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-- Planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 -- -- Ended Quarter with $52.4 million in Cash; Sufficie...

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors
ARLINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research, developme...

Kala Pharmaceuticals Announces Reverse Stock Split
Common Stock Will Begin Trading on Split-Adjusted Basis on October 21, 2022 Common Stock Will Begin Trading on Split-Adjusted Basis on October 21, 2022

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference
ARLINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization o...

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
ARLINGTON, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as an inducement awa...

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
ARLINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research, developmen...

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 -- -- Received $60M Upfront Payment from Sale of EYSUVIS® an...